FDA Advises on Cancer Risks of Elidel and Protopic

Armen Hareyan's picture

Hickory, NC - A potential cancer risk is associated with the increased use of Elidel (pimecrolimus and Protopic (tacrolimus) and the health care professionals are advised by The Food and Drug Administration (FDA) to prescribe these two drugs only as directed and only after other eczema treatments have failed to work.

Share this content.

If you liked this article and think it may help your friends, consider sharing or tweeting it to your followers.